A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults

Annals of African Medicine

Volumn 8, Issue 3, 2009, Pages 147-155

  Habib, Abdulrazaq G ^a  

^a BAYERO UNIVERSITY   (Nigeria)

Author keywords

Antiretroviral Therapy; Drug Resistance; Human Immunodeficiency Virus; Nosocomial; Preventive therapy; Tuberculosis

Indexed keywords

ABACAVIR; AMIKACIN; CAPREOMYCIN; COTRIMOXAZOLE; CYCLOSERINE; ISONIAZID; KANAMYCIN; LAMIVUDINE; NEVIRAPINE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; AFRICA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG COST; ENTERITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION CONTROL; MIXED INFECTION; NIGERIA; REVIEW; SEPTICEMIA; TUBERCULOSIS;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; HIV INFECTIONS; HIV-1; HUMANS; TUBERCULOSIS;

EID: 77749292116     PISSN: 15963519     EISSN: 09755764     Source Type: Journal    
DOI: 10.4103/1596-3519.57236     Document Type: Review

References (49)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing, WHO report 2008. Geneva: World Health Organization 2008.
2. Federal Ministry of Health (2006). National HIV/Syphillis sero-prevalence sentinel survey among pregnant women attending antenatal clinics (2005). Federal Ministry of Health, Abuja, Nigeria.
3. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000;152:247-63.
4. Habib AG. HIV and tuberculosis in Zaria, Nigeria. Nigerian Medical Practitioner 1995;30:23.
5. Habib AG, Keshinro IB, Gebi UI, Olatunde BOM, Onyemelukwe GC, Kangave D. Clinical presentation of HIV-infection in northern Nigeria and its relationship to CD4 + T-cell counts. Nigerian Medical Practitioner 1998;35:3-8.
6. nd ed. Geneva: World Health Organization; 2004.
7. Sani MU, Mohammed AZ, Adamu B, Yusuf SM, Samaila AA, Borodo MM. AIDS mortality in a tertiary health institution: a four year review. J Natl Med Assoc 2006;98:862-6.
8. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993;7:1569-79.
9. Nelson AM, Perriens JH, Kapita B, Okonda L, Lusamuno N, Kalengayi MR, et al. A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: is passive surveillance valid? AIDS 1993;7:1241-5.
10. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access - recommendations for public health approach (2006 revision). Geneva: World Health Organization; 2006.
11. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005;19:2141-8.
12. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006;20:2355-60.
13. Lawn SD, Wood R. When should antiretroviral therapy be started in patients with HIV-associated tuberculosis in South Africa? South African Medical Journal 2007;97:413-5.
14. th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, USA, 25 - 28 February 2007. Abstract #01-126
15. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, Sitti W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV infected patients, Thailand. Emerging Infectious Diseases 2007;13:1001-7.
16. rd annual Infectious Diseases Society of America; San Francisco: 2005.
17. Schiffer JR, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS - a decision analysis. J Acquir Immune Defic Syndr 2007;44:229-34.
18. Oliva J, Moreno S, Sanz J, Ribera E, Molina JA, Rubio R, et al. Co-administration of rifampin and nevirapine in HIV infected patients with tuberculosis. AIDS 2003;17:637-42.
19. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocaña I, et al. Pharmacokinetic interaction between nevirapine and rifampin in HIV infected patients with tuberculosis. JAIDS 2001;28:450-3.
20. Dean GL, Back DJ, De Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999;13:2489-30.
21. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, et al. Efavirenz 600mg/day versus efavirenz 800mg/day in HIV infected patients with tuberculosis receiving rifampicin: 48 weeks result. AIDS 2006;20:131-2.
22. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21:1301-8.
23. Lawn SD, Badri M, Wood R. Tuberculosis among HIV infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-16.
24. Wiktor SZ, Sassan-Marokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75.
25. Grimwade A, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005;19:163-8.
26. Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006;10:946-53.
27. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004;39:1709-12.
28. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
29. Ritacco V, Di Lonardo M, Reniero A, Ambroggi M, Barrera L, Dambrosi A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug resistant tuberculosis in Buenos Aires. J Infect Dis 1997;176:637-42.
30. Ordway DJ, Sonnenberg MG, Donahue SA, Belisle JT, Orme IM. Drug resistant Mycobacterium tuberculosis exhibit a range of virulence for mice. Infection and Immunity 1995;63:741-3.
31. Idigbe O, Sofola T, Akinosho R, Onwujekwe D, Odiah F, Okoye R. Initial drug resistance tuberculosis amongst HIV seropositive and seronegative prison inmates in Lagos, Nigeria. Int Conf AIDS 1998;12:137.
32. Lawson L, Habib AG, Okobi MI, et al. Multi Drug Resistant Tuberculosis (MDR-TB) in Newly Diagnosed Patients in Nigeria. Annals of African Medicine 2008 (in submission)
33. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: University press; 1992.
34. Kayanja HK, Debanne S, King C, Whalen CC. Tuberculosis infection among health care workers in Kampala, Uganda. Int J Tuberc Lung Dis 2005;9:686-8.
35. Harries AD, Kamenya A, Namarika D, Msolomba IW, Salaniponi FM, Nyangulu DS, Nunn P. Delays in diagnosis and treatment of smear-positive tuberculosis and the incidence of tuberculosis in hospital nurses in Blantyre, Malawi. Trans R Soc Trop Med Hyg 1997;91:15-7.
36. Edlin BR, Tokars JL, Grieco MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multi drug resistant tuberculosis among hospitalized patients with the acquire immune-deficiency syndrome. N Eng J Med 1992;326:1514-2.
37. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L, et al. An outbreak of multidrug resitant tuberculosis involving HIV infected patients of two hospitals in Milan, Italy. Italian Multidrug Resistant Tuberculosis Outbreak Study Group. AIDS 1998;12:1095-102.
38. Blumberg HM, Watson DL, Berschling JD, Antle A, Moore P, White N, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995;122:658-63.
39. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care settings, 2005. MMWR Recommend Rep 2005;54:1-141.
40. World Health Organization. Guidelines for the prevention of tuberculosis in healthcare facilities in resource-limited settings. Geneva: WHO/CDS/TB/99.269; 1999.
41. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;1:CD000171.
42. Seyler C, Toure S, Messou E, Bonard D, gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005;172:123-7.
43. Seyler C, Toure S, Messou E, Anglaret X. Risk factors for active tuberculosis in adults on highly active antiretroviral therapy in Africa. AIDS 2006;20:1463-5.
44. Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, Hayes RJ, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003;17:2063-70.
45. Balcells ME, Thomas SL, Godfrey-Fausett P, Grant AD. Isoniazid preventive therapy and the risk for resistant tuberculosis. Emerging Infectious Diseases 2006;12:744-51.
46. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801-8.
47. Grant AD, Charamlambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005;293:2719-25.
48. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-8.
49. Farmer PE, Leandre F, Mukherjee J, Gupta R, Tarter L, Kim J Y. Community-based treatment of advanced HIV disease: Introducing DOT-HAART [Directly Observed Therapy with Highly Active Anti Retroviral Therapy]. Bulletin of World Health Organization 2001;79:1145-51.